Intraocular lenses (IOLs), implanted in the eye as treatment for cataracts or myopia, are a growing global market in an ageing population, one estimated to be worth more than $4.5 billion by 2022.

The eye's natural crystalline lens can be replaced with an artificial lens—known as an intraocular lens—to restore clarity and lead to a vast improvement in quality of life for patients with cataracts ...

Please provide your email address to receive an email when new articles are posted on . In 2013, Malvina B. Eydelman, MD, director of the FDA’s Division of Ophthalmic and Ear, Nose and Throat Devices, ...

The report published on the global Intraocular Lens (IOL) is a comprehensive analysis of the various factors that either positively or negatively affect market growth. The report also introduces the ...

JACKSONVILLE, Fla.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth of focus (EDOF) intraocular lens ...

Copenhagen, Denmark: Patients who have a new type of lens implanted in their eyes during surgery for cataracts or to correct their eyesight have excellent or good vision over distances both near and ...